The purpose of this retrospective registry study was to investigate the outcome of autoSCT for primary mediastinal B-cell lymphoma (PMBCL) in the rituximab era, including the effects of eventual post-transplant radiotherapy (RT) consolidation. Patients with PMBCL aged between 18 and 70 years who were treated with a first autoSCT between 2000 and 2012 and registered with the EBMT were eligible. Eighty-six patients with confirmed PMBCL and the full data set required for this analysis were evaluable. Sixteen patients underwent autoSCT in remission after first-line therapy (CR/PR1), 44 patients were transplanted with chemosensitive relapsed or primary refractory disease (CR/PR >1), and 24 patients were chemorefractory at the time of autoSCT. With a median follow-up of 5 years, 3-year estimates of relapse incidence, progression-free survival, and overall survival were 6%, 94%, and 100% for CR/PR1; 31%, 64%, and 85% for CR/PR >1; and 52%, 39%, and 41% for REF, respectively. Whilst there was no significant benefit of post-transplant RT in the CR/PR >1 group, RT could completely prevent disease recurrence post d100 in the refractory group. In conclusion, autoSCT with or without consolidating RT is associated with excellent outcome in chemoimmunotherapy-sensitive PMBCL, whereas its benefits seem to be limited in chemoimmunotherapy-refractory disease.
Introduction
Primary mediastinal B-cell lymphoma (PMBCL) is a rare aggressive B-cell malignancy. Although formally considered as diffuse large cell lymphoma (DLBCL) subtype, its genetic and immunophenotypical features share similarities with nodular sclerosing Hodgkin lymphoma rather than with other DLBCL. Clinically it is characterised by bulky mediastinal involvement, typically without systemic dissemination, with the majority of the patients being young adults with a female preponderance [1] .
Whilst in the pre-rituximab era the prognosis of PBMCL appeared to be inferior to that of other DLBCL, the addition of rituximab to standard CHOP (cyclophosphamide, doxorubicine, vincristin, prednisone)-based induction therapy has significantly improved the outcome of PMBCL, now being comparable to that of DLBCL [1, 2] . Following the treatment algorithms of DLBCL, most patients receive consolidating radiotherapy (RT) as part of first-line treatment, albeit the benefit of this strategy is debated, in particular in patients in complete clinical or metabolic response after first-line chemo immuno radiotherapy (CIT) [1, [3] [4] [5] . Nevertheless, some patients still fail to achieve sustained disease control, largely because of being primary refractory or early (within the first 12 months) relapse [1, 4, 6] . It is still not settled if this can be avoided by fist-line CIT intensification with or without autologous stem cell transplantation (autoSCT) [1, 4] .
Management of relapsed and refractory PMBCL is much less well studied. In analogy to DLBCL, autoSCT has been recommended for the PMBCL salvage setting, but this is largely relying on data from the pre-rituximab era [7, 8] , whereas systematic analyses evaluating autoSCT and its possible place in the current treatment algorithm of PMBCL are sparse. The purpose of the present registry study was to investigate the outcome of autoSCT for PMBCL in the rituximab era. The results suggest that in CIT-sensitive PMBCL, autoSCT is associated with durable progressionfree survival independent of treatment line, whilst its benefit in CIT-refractory disease appears to be limited.
Patients and methods

Data source
EBMT is a voluntary organisation comprising more than 500 transplant centres mainly from Europe. Accreditation as a member centre requires submission of minimal essential data (MED-A form) from all consecutive patients to a central registry in which patients may be identified by the diagnosis of underlying disease and type of transplantation. Informed consent for transplantation and data collection was obtained locally according to the regulations applicable at the time of transplantation. Since January 1 2003, all transplant centres have been required to obtain written informed consent prior to data registration with the EBMT following the Helsinki Declaration 1975.
Study design
This was a registry-based retrospective multicentre study including patients 18 years or above who underwent autoSCT for PMBCL between 2000 and 2012. Baseline patient, disease and transplant data were collected from MED-A forms. Centres with potentially eligible patients were contacted to provide additional data, including chemotherapeutic pre-treatment, pre-and post-transplant RT, and updated follow-up information. In addition, submission of a written diagnostic histopathology report confirmatory for PMBCL was mandatory for inclusion in the study.
Definitions
For the purpose of this analysis, refractory and untreated relapse, stable disease and progressive disease were grouped together as chemorefractory disease. Complete response (CR), partial response (PR) and sensitive relapse (based on computed tomography (CT) results) were categorised as chemosensitive disease. Only those patients who went directly into remission by first-line CIT +/− consolidating RT were considered as CR/PR1, whereas patients who had been primary refractory and achieved their first response only after salvage CIT or RT were assigned to the CR/PR >1 group.
Statistical analysis
Statistical analysis was descriptive and employed log-rank comparisons for univariate assessment of the impact of baseline characteristics on survival endpoints. Co-primary end points studied were overall survival (OS) and progression-free survival (PFS) after autoSCT. OS was defined as the time from autoSCT to death from any cause and PFS was defined as the time from autoSCT to relapse or progressive disease or death from any cause, whatever came first. Secondary endpoints were incidence of disease relapse or progression (IR) and non-relapse mortality (NRM). Progression was defined as any increase in the size of sites of disease, the development of new sites of disease or the recurrence of disease after autoSCT. NRM was defined as death from any cause in the absence of prior post-transplant disease relapse or progression. The probabilities for OS and PFS were estimated from the time of autoSCT using the Kaplan-Meier product-limit estimate and were compared by the log-rank test in univariate analysis. Estimates of NRM and IR were calculated using cumulative incidence rates to accommodate competing risks and were compared by Gray's test. The following covariates were analysed in univariate analyses: patient age and sex, performance status, size of mediastinal mass at presentation, B symptoms at diagnosis, disease stage, time interval between diagnosis and autoSCT, number of prior lines of therapy, exposure to rituximab, intensity of induction chemotherapy, pretransplant administration of RT, disease status at transplantation and stem cell source. Post-transplant RT was also analysed as a time-dependent variable. Multivariate analysis has not been performed due to the small number of patients and events. In order to assess the impact of post-transplant consolidative RT, a landmark analysis evaluating the impact of administrating RT within 3 months post-transplant on IR, PFS, and OS was performed. The landmark analysis for IR and PFS included only patients alive with no evidence of disease relapse/progression within the first 3 months post transplantation. Landmark analyses were performed for all patients and according to disease status at autoSCT.
All p-values < 0.05 were considered significant. All statistical analyses were performed using R 2.15.3 (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org).
Results
Study population
Altogether 149 patients were identified in the database with an informative data set consistent with the eligibility criteria for this study. A complete extended data set including follow-up data and the diagnostic report was provided on request for 100 (67%) patients. Of these, 14 patients were excluded because the diagnostic report was considered as not confirmative for the diagnosis of PMBCL after central review. The final cohort for analysis therefore included 86 patients (Suppl. Figure 1) 
Patient characteristics
Characteristics of the 86 included patients are detailed in Table 1 . Almost half of the patients were men, and median age was 35 years. A relatively large proportion (40%) had advanced-stage disease at diagnosis. Sixty-three patients (73%) were treated with CHOP or CHOP-like induction therapy and 23 (27%) received a more intensive regimen. Median time from diagnosis to autoSCT was 12 months. A vast majority of patients (86%) had been exposed to rituximab prior to autoSCT. High-dose therapy for autoSCT was BEAM (carmustine, etoposide, cytarabine, melphalan) in 75% of the patients.
Disease status at transplantation was as follows: 16 patients (19%) were in remission after first-line chemotherapy (CR/PR1); 44 patients (51%) were transplanted in partial or complete remission, achieved after salvage therapy for primary refractory or relapsed disease (CR/PR >1); and 24 patients (28%) were transplanted with refractory disease (including a single patient with untreated relapse). Remission status at autoSCT could not be assigned in two patients (2%). There were no differences in terms of baseline characteristics between the three groups, although refractory patients tended to have larger mediastinal masses and more often B symptoms at diagnosis. Expectedly, disease status correlated with the extent of chemotherapy pretreatment (Table 1) . Whereas in the CR/PR1 group only two patients had received consolidating RT prior to transplant, in the CR/PR >1 group 16 patients had received pretransplant RT, 14 of them as part of (failed) first-line therapy, and two patients for consolidation of salvage therapy bridging to transplant. In the refractory group, eight patients had received and failed RT prior to autoHSCT (Suppl. Figure 2 ).
In the CR1/PR1 group, three out of 13 patients (23%) with information available received consolidating posttransplant RT, defined as RT administered within 3 months after autoSCT in the absence of prior post-transplant PMBCL progression. In the CR/PR >1 group, 12 out of 36 patients (33%) with information available received consolidating post-transplant RT, and another one therapeutic RT for disease relapse. Two of the 13 patients from this group who had post-transplant RT had already been irradiated prior to autoSCT. Among the refractory patients, consolidation RT was given to 8/23 patients (35%), and therapeutic RT to 3/23 patients (13%) post-transplant. Three of the 11 patients from this group who had post-transplant RT had already been irradiated prior to autoSCT (Suppl. Figure 2 ).
Outcome
At 100 days post-transplant, a CR was reported for 46 out of 80 patients (58%) evaluable for this landmark. Whilst 19 of these were already in CR at autoSCT, remission status improved from PR pre-transplant to CR post-transplant in 22 patients, and from refractory disease to CR in four patients (pre-transplant disease status unknown in the remaining patients). In eight out of 19 PR → CR patients with information available, consolidating post-transplant RT had been administered, and also in all four refractory patients who had achieved CR at d100. Overall, 100d CR rates in the CR/PR1, CR/PR >1, and refractory groups were 67%, 72%, and 19%, respectively.
At a median observation time of survivors of 60 months (IQR 32-90 months), 62 patients were alive and 23 had died; five due to transplant related causes and 18 subsequent to PMBCL recurrence. The causes of non-relapse death were infections (n = 3), liver failure (n = 1) and secondary malignancy (n = 1). Overall, post-transplant disease recurrence was observed in 26 patients at a median time of 3.6 (IQR 2.2-6.0) months, with only three events occurring beyond 1 year after autoSCT. The cumulative incidence of relapse/progression at 3 and 5 years post-autoSCT were 34% (95% confidence interval 24-45%) and 34% (24-45%), respectively, translating into 3-and 5-year probabilities for PFS and OS of 62% (52-74%) and 62% (52-74%) and 75% (65-85%) and 71% (61-82%), respectively (Fig. 1) .
If broken down by disease status at autoSCT (CR/PR1 vs. CR/PR >1 vs. refractory), 5-year estimates were 6% (0.4-25%), 31% (17-46%), and 52% (30-70%) for IR; 94% (83-100%), 64% (50-81%), and 39% (23-65%) for PFS; and 100% (100-100%), 77% (64-93%), and 41% (25-68%) for OS, respectively. These results reflect a statistically significant inferiority of refractory disease status for all three endpoints (Fig. 2a-c) . Of note, there was no statistically significant difference in PFS between patients transplanted in >PR1 and those transplanted with >CR1 (p = 0.842). In addition, univariate comparisons showed a significantly adverse impact of poor performance status at transplantation on IR, PFS, and OS. In contrast, age, gender, size of mediastinal mass at presentation, B symptoms, time interval between diagnosis and autoSCT, number of prior lines of therapy, exposure to rituximab, intensity of induction chemotherapy, pre-transplant RT, and stem cell source had no statistically significant on any endpoint (Table 2) . Notably, none of the 13 rituximab-naïve patients who proceeded to autoSCT experienced post-transplant PMBCL recurrence despite three patients being refractory.
A landmark analysis showed no statistically significant benefit of consolidating RT performed within 3 months post-autoSCT, for IR, PFS, or OS in patients transplanted in 1CR/PR >1 (p = 0.99, 0.67, 0.56, respectively). In contrast, consolidative radiotherapy was associated with a tendency for relapse prevention in refractory patients (p = 0.068, 0.23, and 0.27, for IR, PFS, and OS, respectively) (Fig. 3) .
Discussion
The introduction of CIT and other advances have largely improved the results of first-line therapy of patients with PMBCL. Even so, primary induction failure and early relapse remain a problem in this disease. Although salvage chemotherapy followed by autoSCT is commonly performed in this setting, disease-specific evidence for the usefulness of this policy in the rituximab era is sparse. The present study is the first one analysing salvage autoSCT in a sizable sample of patients with relapsed/ refractory PMBCL after rituximab-based CIT. In particular, in chemosensitive patients, the 5-year PFS of 63% observed here compares well with results obtained with autoSCT in the general DLBCL salvage setting. A recent EBMT study on a very large sample reported 48% PFS at 4 years after autoSCT for chemosensitive DLBCL [9] . This is in line with a 3-year PFS of 44% described in another registry study focussing on early DLBCL relapses after rituximabbased induction [10] , as well as with the 4-year event-free survival of sensitive patients treated with salvage autoSCT in the CORAL trial [11] . Moreover, the high conversion rate from pre-transplant PR into long-term CR observed here suggests this modality to be remarkably active in chemosensitive relapsed PMBCL. Unfortunately, response assessment could not be validated by PET scan results in this registry study. However, the complete lack of difference in outcome between patients transplanted in CR >1 opposed to those transplanted in PR >1 supports the notion that PR patients, even if not evaluated by PET scan, represent a truly chemosensitive group.
Of note, and in contrast to other DLBCL, the sustainability of the disease control achieved with autotransplant in the sensitive PMBCL patients discussed here, with virtually no relapses beyond 12 months post-transplant. This figure resembles that achieved in PMBCL first-line treatment, where primary refractoriness and early relapse make up the bulk of treatment failures [3] . Our encouraging results are in line with a smaller (n = 37) Japanese study on rituximabexposed relapsed/refractory PMBCL, reporting a 4-year OS of 72% [12] .
Similar to other DLBCL, the results of autoSCT in this PMBCL series were significantly worse in patients transplanted with a poor performance status. Unfavourable outcome was also observed in patients who underwent transplant with refractory disease. Albeit the durable 3-year PFS of 39% appears to compare favourably with the outcome of autoSCT for refractory DLBCL observed elsewhere [9, 13] , the contribution of high-dose therapy here is difficult to assess given the confounding effects of RT in this subset. In any case, chemorefractory PMBCL represents an unmet medical need. To this end, novel therapeutics may help to break refractoriness in PMBCL having failed first-line therapy [14, 15] , or induction failure may be prevented by sophisticated early CIT intensification [1] .
The current study was not designed to evaluate the outcome of PMBCL patients who failed rituximab-containing induction, but to assess the outcome of those eventually treated with autoSCT. There is no doubt that a substantial number of those who progress following induction are refractory to subsequent therapies and, therefore, are not considered for autoSCT [16] . The proportion of these "unfavourable", non-responding patients remains speculative, but it is likely that it is considerable, given the adverse effect of prior exposure to rituximab on response to salvage chemotherapy in other DLBCL [11, 17, 18] . The finding that the few rituximab-naïve patients in our series had a remarkably good outcome is in keeping with these observations. Rituximab exposure was not considered as covariate in our risk factor analyses because rituximabnaïve patients do not occur in the current treatment reality anymore.
Whilst a role for post-autoSCT RT consolidation could not be confirmed in chemosensitive salvage patients, administration of post-transplant irradiation seems to have prevented PMBCL recurrence in some patients autografted with chemorefractory disease. However, the sample size of this subset was small, and post-autoSCT RT may not be an option in many patients because of pre-transplant RT exposure. This also implies that theoretically the biological condition predisposing to failing pre-transplant RT rather than not receiving post-transplant RT could have been the cause of the poor outcome of refractory patients not undergoing post-SCT irradiation.
Finally, our study proved an excellent outcome of those patients who received autoSCT for consolidation after successful first-line CIT. However, since these patients present a selective group of patients that have a very good a NR-the risk for relapse for these variable cannot be estimated due to lack of relapses in the few patients, presenting with BM involvement and in those receiving a non-rituximab-based therapy prognosis anyway [1, 4] , this result does not permit the conclusion that autoSCT should be routinely considered as part of primary treatment in PMBCL.
The limitations of this analysis are the genuine shortcomings of transplant registry studies, namely the retrospective character and selection bias. On the contrary, strengths consist in the central review of diagnostic reports, detailed dissection of the interplay with post-transplant RT, and the informative observation time and sample size which is the largest on autoSCT in PMBCL in the rituximab era to date.
In summary, in CIT-sensitive relapsed PMBCL, autoSCT appears to be associated with excellent outcome, with no clear effect of additional consolidating RT. In contrast, in CIT-refractory PMBCL, the benefits of autotransplantation seem to be limited, in particular if posttransplant RT cannot be administered. Larger prospective studies are warranted to corroborate these findings, and to define the exact role of post-transplant irradiation in this setting in the PET era. Relapse in the patients transplanted with refractory disease, dependent on exposure to radiotherapy within 3 months post autoSCT PSF in the patients transplanted with refractory disease, dependent on exposure to radiotherapy within 3 months post autoSCT OS in the patients transplanted with refractory disease, dependent on exposure to radiotherapy within 3 months post autoSCT Fig. 3 Outcome of patients dependent on disease status at transplantation and post-transplant irradiation outcome
